If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksprobiotix health Regulatory News (PBX.PL)

Share Price Information for probiotix health (PBX.PL)

Share Price is delayed by 15 minutes
Get Live Data
7.75    0.00 (0.00%)
Bid:
7.50
Ask:
8.00
Spread: 0.50 (6.667%)
Market Cap: £12.26m
PBX.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday probiotix health Share Chart

New appointment

24 Jul 2023 07:00

RNS Number : 8537G
Probiotix Health PLC
24 July 2023
 

ProBiotix Health plc

("ProBiotix" or the "Company")

 

New appointment

 

ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces the appointment of Niels Peter Bak ("Niels Peter") as Technical Product Manager, effective from 1 September 2023.

 

Niels Peter has been brought on to the team as a pivotal part of executing the Company's strategy to focus the business towards finished supplement dosage formats. In line with the Company's defined strategic approach, Niels Peter will be heading up the product management function, with a specific focus on strengthening the infrastructure of ProBiotix, further accelerating product development and increasing the responsiveness to individual customer requirements. Niels Peter is a talented industry veteran with a proven track record in strategy execution, business to business product management, product development and technical marketing.

 

Niels Peter has almost 30 years' experience in international roles in the global probiotics space across a number of well-known organisations. He was an integral part of the team at Bifodan A/S, where he specialised in product portfolio development and operational product management and was instrumental in bringing the company's women's health probiotic product line onto the market. Following the acquisition of Bifodan A/S by Deerland, he assumed a managerial role involving probiotic solutions. Prior to this, Niels Peter worked at global bioscience company, Chr. Hansen, in the probiotics division across a number of technical product and marketing roles from 1989 until 2006.

 

Steen Andersen, CEO of ProBiotix Health plc commented: "Niels Peter's experience and track record of maintaining and expanding product portfolios to support growing sales, along with his network of industry contacts within the probiotics industry, will help us in our next phase of development. Niels Peter's appointment comes at an opportune time, now that we have established international sales and brand awareness of our award winning LPLDL® probiotic ingredient and our CholBiome® finished format product line. His appointment will allow us to further capitalise on our efforts so far, as we increase our access to the European and North American markets."

 

For further information, please contact:

 

ProBiotix Health plc

https://probiotixhealth-ir.com/

Steen Andersen, Chief Executive

Contact via Walbrook below

Peterhouse Capital Ltd (AQSE Corporate Adviser and Broker)

Tel: 020 7469 0930

Mark Anwyl

Duncan Vasey

 

Walbrook PR Ltd

probiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXBUGDRGDDDGXB
12
Date   Source Headline
15th Aug 20247:00 amRNSNew commercial partnership agreement in China
8th Aug 20242:14 pmRNSResult of AGM
15th Jul 20247:00 amRNSSix month trading update
28th Jun 20247:00 amRNSFinal Results
26th Feb 20247:00 amRNSPartner agreement with SymbioPharm
9th Feb 20247:00 amRNSChange of auditor
31st Jan 20247:00 amRNSNew appointment
11th Jan 20247:00 amRNSDirectorate Change
27th Sep 20237:00 amRNSHalf-year Report
1st Aug 20237:00 amRNSDistribution agreement
26th Jul 202312:34 pmRNSResult of AGM
24th Jul 20237:00 amRNSNew appointment
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.